Tobacco Use, Perceptions, and Characteristics of Adults Who Use IQOS[®] in the United **States: Findings from a Cross-Sectional Study**

Introduction

The smoke-free heated tobacco product IQOS[®] was granted a Premarket Tobacco Product Marketing order from the United States (US) Food and Drug Administration in 2019 and was granted a Modified Risk order in 2020. IQOS[®] was commercially available from 2019 to Nov. 2021 in the US.

The aim of this study was to describe selected sociodemographic characteristics of adults who used IQOS[®] (AUI), tobacco use patterns relevant to IQOS[®] use, risk perceptions of IQOS[®], and understanding of IQOS[®] MRTP messages among AUI.

Methods

Design: Cross-sectional survey


- Study population: AUI aged 21 and older who had used at least 100 Marlboro[®] HeatSticks by the time of recruitment
- Recruitment: Direct mail and emails to consumers registered
- in the IQOS[®] consumer database
- Assessment: Online survey

Time of Data Collection: September to November 2021

- IQOS [®] MRTP claim: AVAILABLE EVIDENCE TO DATE:

- chemicals.

Results



Strengths and Limitations

Strengths

- Assessed real-life behaviors in a postmarket environment
- Time-centered questions to establish temporality
- Leveraged IQOS[®] consumer database

Conclusion

Our results from a comprehensive assessment of behaviors and perceptions in a realworld setting among established AUI in the US provide supportive evidence that IQOS[®] has the potential to help smokers reduce smoking or switch.

Limitations


- Observational study
- Self-report

The IQOS system heats tobacco but does not burn it. This significantly reduces the production of harmful and potentially harmful chemicals. Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body's exposure to harmful or potentially harmful

- Cessation treatment use
 - 52% never
- 31% >12 months ago
- 6% <=12 months
- 7% don't know or refused

Relatively low response level

> Almost all AUI had smoked combusted cigarettes before trying IQOS[®]. \triangleright At the time of assessment, 51% were NOT smoking combusted cigarettes. > Among AUIs who were smoking, 84% smoked fewer cigarettes compared to before trying IQOS[®]. > >80% had correct understanding of the modified risk message of IQOS[®].



This scientific research is presented by Altria Client Services LLC (ALCS). ALCS affiliate companies are tobacco product manufacturers.

Hui Cheng¹, Brendan Noggle¹, Andrea Vansickel¹, Edward Largo¹, Pierpaolo Magnani² ¹Altria Client Services LLC, Richmond, VA, USA ²Philip Morris Products S.A., Lausanne, Switzerland TSRC, September 2023



Altria

Science